Rigorous testing has resulted in observations of the Optejet’s durable base unit performing over 30,000 sprays, and 98% of ...

NEW YORK – Eyenovia, Inc., a pharmaceutical company specializing in preparations, announced today a reverse stock split of its common shares in a strategic move to comply with Nasdaq's minimum bid ...

Eyenovia (EYEN) announces recent progress on the development of its user-filled spray dispenser. “Millions of consumers have difficulty with ...

H.C. Wainwright maintained a neutral stance on Eyenovia (NASDAQ:EYEN) shares, reiterating a price target of $2.00. The firm's analyst, Matthew Caufield, highlighted the U.S. Food and Drug ...

Eyenovia, Inc. announced on January 15, 2025, that leading proxy advisory firms ISS and Glass Lewis have advised stockholders to vote in favor of a proposed reverse stock split at a ratio between ...

Eyenovia announces progress on its user-filled Optejet eye drop dispenser, aiming for U.S. regulatory approval in late 2025. Eyenovia, Inc. has made significant advancements in the development of ...

Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the prior year, the firm earned ($0.18) earnings per share.

Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20thNEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its ...

Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ( ...